🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being described as a "major milestone" in the fight against drug-resistant strains of the bacteria, according to scientists.

An International Challenge

Cases of gonorrhoea are increasing around the world, with estimates suggesting in excess of 82 million infections each year. Especially elevated rates are reported in the African continent and countries within the World Health Organization's designated area, which encompasses China and Mongolia to New Zealand. Within England, cases have reached a record high, while infection numbers across Europe in 2023 were triple the level compared to those in 2014.

“The approval of fresh medications for gonorrhoea is an significant and necessary advancement in the context of rising global incidence, escalating drug resistance and the very limited treatment choices at this time.”

Public health authorities are particularly alarmed about the increase in drug-resistant strains. The WHO has listed it as a "critical concern". Recent surveillance found that the effectiveness of primary antibiotics like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Recent Treatment Options Receive Authorization

Zoliflodacin, alternatively called Nuzolvence, was authorized by the American regulatory agency in recent days for use against gonorrhoea. This disease can lead to major issues, including infertility. Researchers hope that targeted use of this new drug will help hinder the emergence of superbugs.

Another new antibiotic, originating from the pharmaceutical company GSK, was also approved in the same week. This treatment, which is additionally indicated for UTIs, was proven in research to be effective against superbug versions of the gonorrhoea bacteria.

An Innovative Approach to Creation

Zoliflodacin was the result of a unique collaborative effort for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the pharmaceutical company Innoviva to develop it.

“This milestone represents a major breakthrough in the therapy of superbug gonorrhoea, which until now has been outpacing medical innovation.”

Testing Results and Worldwide Availability

Based on data detailed in a major medical journal, the new drug eradicated over nine in ten of uncomplicated infections. This places it at an equal footing with the existing first-line therapy, which uses two antibiotics. The trial enrolled hundreds of participants from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its unique model, the non-profit has the rights to make available and distribute the drug in a wide range of regions with limited resources.

Clinicians treating patients have voiced hope. Having a easy-to-administer therapy such as this is described as a "critical tool" for public health efforts. This is considered crucial to reduce the burden of the infection for people and to halt the transmission of extremely resistant gonorrhoea globally.